Figure 5 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib
Year: 2026
Type: other
Abstract: SLFN11 expression in multiple myeloma (MM) cell lines and SLFN11 translocation to nucleoli by BTZ. A, Correlation between the expression of SLFN11 and SLFN13 in the Cancer Therapeutics Response Portal (CTRP)–Broad–MIT cell line database (https://discover.nci.nih.gov/cellminercdb/). Correlation coefficient and P value are indicated above the figure. B, Representative SLFN11 immunoblots in MM.1S, KMS-34, and KMS-27 cell lines. Human osteosarcoma cell line U2OS was used as a negative control. C, Scheme of the nucleolus comprising the fibrillar center, the dense fibrillar component, and the granular component. D, Representative immunofluorescence images showing total SLFN11 (green, left, no preextraction) and chromatin-bound SLFN11 (green, right) with nucleolin (red) and DAPI (blue) in MM.1S and KMS-34 cells after 4-hour treatment with BTZ [0.5 μmol/L (MM.1S), 5 μmol/L (KMS-34)] or CPT [1 μmol/L (MM.1S), 5 μmol/L (KMS-34)]. Scale bars, 10 μm. E, Representative immunofluorescence images showing total chromatin-bound SLFN11 (green) with UBF (red) and DAPI (blue) in KMS-34 cells after 4-hour treatment. Scale bars, 10 μm. F, Representative immunofluorescence image showing BTZ-induced SLFN11 nucleolar translocation in U2OS with DOX-inducible SLFN11 expression. Cells were treated with CPT or BTZ (1 μmol/L) for 4 hours.
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7171398534
Cites:
Cited by:
Related to: